Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Event Reporting Harmonization Is Goal Of Joint FDA/NIH Task Force

Executive Summary

An HHS task force is preparing to release a guidance on harmonizing the federal government's clinical adverse event reporting policies

You may also be interested in...



Sponsors Should Manage Adverse Event Reports To Reduce IRB Burden – Lilly

Sponsors should be responsible for oversight of adverse event safety data review to reduce institutional review board burden, Lilly Project Leader Vish Watkins says

Sponsors Should Manage Adverse Event Reports To Reduce IRB Burden – Lilly

Sponsors should be responsible for oversight of adverse event safety data review to reduce institutional review board burden, Lilly Project Leader Vish Watkins says

Aleve Warning Gives Pfizer Some Relief, But Is New Headache For FDA

Data from a National Institutes of Health study on Alzheimer's disease prevention showing a cardiovascular safety signal for naproxen present a new challenge for FDA in regulating COX-2 inhibitors

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel